Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Kinase Inhibitor ◽

Long Term Follow Up

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Leukemia ◽

10.1038/s41375-019-0658-7 ◽

2019 ◽

Vol 34 (5) ◽

pp. 1458-1461 ◽

Cited By ~ 6

Author(s):

Simon A. Rule ◽

Guillaume Cartron ◽

Christopher Fegan ◽

Franck Morschhauser ◽

Lingling Han ◽

...

Keyword(s):

Tyrosine Kinase ◽

Mantle Cell Lymphoma ◽

Kinase Inhibitor ◽

Cell Lymphoma ◽

Mantle Cell ◽

Long Term Follow Up

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Annals of Oncology ◽

10.1093/annonc/mdw228 ◽

2016 ◽

Vol 27 (9) ◽

pp. 1794-1799 ◽

Cited By ~ 43

Author(s):

E. Ben-Ami ◽

C.M. Barysauskas ◽

M. von Mehren ◽

M.C. Heinrich ◽

C.L. Corless ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Multicenter Phase ◽

Tyrosine Kinase Inhibitor Therapy ◽

Long Term Follow Up ◽

Gi Stromal Tumor

Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia

Leukemia & Lymphoma ◽

10.1080/10428194.2016.1247957 ◽

2016 ◽

Vol 58 (6) ◽

pp. 1502-1505 ◽

Cited By ~ 1

Author(s):

Richard R. Furman ◽

Ying Luan ◽

Elizabeth Bilotti ◽

Thorsten Graef

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Waldenström’S Macroglobulinemia ◽

Previously Treated ◽

Waldenstrom's Macroglobulinemia ◽

Waldenström's Macroglobulinemia

Faculty Opinions recommendation of Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726479284.793535657 ◽

2017 ◽

Author(s):

Florence Duffaud

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Multicenter Phase ◽

Tyrosine Kinase Inhibitor Therapy ◽

Long Term Follow Up ◽

Gi Stromal Tumor

Separation of Bruton’s tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography

Journal of Chromatography A ◽

10.1016/j.chroma.2018.12.006 ◽

2019 ◽

Vol 1586 ◽

pp. 106-115 ◽

Cited By ~ 5

Author(s):

Shiuhang Henry Yip ◽

Dauh-Rurng Wu ◽

Peng Li ◽

Dawn Sun ◽

Scott H. Watterson ◽

...

Keyword(s):

Tyrosine Kinase ◽

Supercritical Fluid ◽

Supercritical Fluid Chromatography ◽

Kinase Inhibitor ◽

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability

Molecular Pharmaceutics ◽

10.1021/acs.molpharmaceut.8b00702 ◽

2018 ◽

Vol 15 (11) ◽

pp. 5124-5134 ◽

Cited By ~ 4

Author(s):

Stéphanie van Hoppe ◽

Johannes J. M. Rood ◽

Levi Buil ◽

Els Wagenaar ◽

Rolf W. Sparidans ◽

...

Keyword(s):

Cytochrome P450 ◽

Tyrosine Kinase ◽

Oral Bioavailability ◽

Kinase Inhibitor ◽

Cytochrome P450 3A ◽

Brain Penetration ◽

P Glycoprotein

Development of an Efficient Manufacturing Process for Reversible Bruton’s Tyrosine Kinase Inhibitor GDC-0853

Organic Process Research & Development ◽

10.1021/acs.oprd.8b00134 ◽

2018 ◽

Vol 22 (8) ◽

pp. 978-990 ◽

Cited By ~ 6

Author(s):

Haiming Zhang ◽

Theresa Cravillion ◽

Ngiap-Kie Lim ◽

Qingping Tian ◽

Danial Beaudry ◽

...

Keyword(s):

Tyrosine Kinase ◽

Manufacturing Process ◽

Kinase Inhibitor ◽

Efficient Manufacturing

Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib

Future Medicinal Chemistry ◽

10.4155/fmc-2017-0145 ◽

2018 ◽

Vol 10 (3) ◽

pp. 343-356 ◽

Cited By ~ 4

Author(s):

Linyi Liu ◽

Bingyu Shi ◽

Xiangqian Wang ◽

Hua Xiang

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Resistance Mutations ◽

Bruton’s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells

International Immunopharmacology ◽

10.1016/j.intimp.2020.106215 ◽

2020 ◽

Vol 80 ◽

pp. 106215 ◽

Cited By ~ 2

Author(s):

Ahmed Nadeem ◽

Sheikh F. Ahmad ◽

Naif O. Al-Harbi ◽

Ahmad M. El-Sherbeeny ◽

Abullah F Alasmari ◽

...

Keyword(s):

Tyrosine Kinase ◽

Immune Cells ◽

Kinase Inhibitor ◽

Innate Immune ◽

Innate Immune Cells ◽

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)

10.1021/bk-2019-1332.ch009 ◽

2019 ◽

pp. 239-266

Author(s):

James J. Crawford ◽

Haiming Zhang

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽